

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE
HELD ON THURSDAY 30th APRIL 2015 AT 2.00PM
ENTERPRISE HOUSE, KENDAL**

Present:	Bill Glendinning Lesley Angell Pauline Bourne Helen Huck Andrea Loudon Ben Merriman Dr Andrea Mulgrew Sarah Roberts Dr Julia Smith Phil Utting	Chief Pharmacist, NCUHT (Chair) Medicines Optimisation Team Lead, NECS Senior Pharmacist, UHMB Lead Pharmacist, CPFT Clinical Pharmacy Lead, CCG LPC Representative GP Prescribing Lead, Allerdale Locality Patient Voice representative GP Prescribing Lead, South Lakes Locality Senior Technician, Medicines Optimisation, NECS
----------	---	---

In Attendance: Judi Matthews

25/15 **APOLOGIES FOR ABSENCE** *Action*

Apologies for absence were received from:
 Dr Charlotte Asquith, GP, Carlisle, LMC Representative
 Dr Amanda Pugh, GP Prescribing Lead, Furness Locality
 Tim Slaughter, Medicines Optimisation Pharmacist, NECS

26/15 **DECLARATION OF INTERESTS**
 AL is NICE Associate.

27/15 **MINUTES OF THE PREVIOUS MEETING**

The minutes of the previous meeting held on 9 October 2014 were agreed subject to the following amendments:
 06/15 Sildenafil, Implications of Change of SLS Status – amend to: The only exception is if the patients request Viagra and do not meet the SLS criteria.
 14/15 Nutritional Support in Nursing Care Homes – LA to ask ND about the involvement of nutritional support team.
 21/15 prescribing of Valproate in pregnancy – LA has already initiated a pop up in Scriptswitch.

28/15 **ACTION LOG FROM PREVIOUS MEETING (30 April 2015)**

Updates were given as follows:

14/013 – this item is completed	15/06 - this item is completed
14/041 – this item is completed	15/07 – this item is completed
14/020 – this item is completed	15/10 – this item is completed
14/047 – this item is completed	15/11 – this item is completed
15/02 – this item is completed	
15/03 – this item is completed	
15/04 – this item is completed	
15/05 – this item is completed	

21/14 - "Just in Case" Sheet

Endorsed by the APC. JM to liaise with Palliative Care Group regarding implementation and training.

AL

Committee noted confusion over commissioning Community Pharmacy enhanced service.

69/14 – DMARDS Monitoring

ACTION : PB to meet next month with Rheumatology Consultants and to liaise with BG with a view to adopt the North Lancashire Shared Care Guidelines.

PB
BG

70/14 – Revised Dosing for Domperidone use in babies and children position statement

PB

ACTION : PB to bring draft Domperidone SCG to next meeting.

85/14 – Primary Care Management of Cellulitis

AL will attend cellulitis pathway meeting on 15/05/15 to discuss the diagnosis, treatment of cellulitis, benefits of IV, antibiotic choice and agent.

AL

ACTION – AL to update about progress with designing a pathway for IV antibiotics in cellulitis.

107/14 & 19/15 – Comments on Draft PPI's Algorithm

PB to feedback the APC comments. Concerns over the prescribing of Gaviscon Advance or Peptac. Prescribing of an Alginate requested instead of a brand.

ALL

111/14 – Proposal for the use of NOACS for cardioversion.

PB

Ongoing, Dr Brodison to attend the North Lancs APC.

114/14 - Bring proposal for dementia patients reviews as part of the SCG

HH

Ongoing , Darren Reynolds to attend the next meeting.

134/14 – Draft a statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decision of the IFR panel.

AL

Ongoing

05/15 – COPD Guidelines

NCUHT Respiratory Consultants would prefer to adopt Gold Guidelines, the committee noted the comments but the guidelines must comply with NICE Guidance. It was suggested that drug names appeared in the flowchart.

LA

LA to incorporate comments distribute the amended treatment guide.

16/15 Branded Generics

The APC supported the paper in principle but requested rewording the statement to stress generic prescribing with specified exemptions.

TS

ACTION: AL to speak to TS about rewording the paper.

20/15 – Sick Day Medication

PB to circulate AQA document to members.

PB

21/15 – Mycophenolate mofetil

PB

Ongoing

22/15 – NCUHT Draft MMC Minutes (5Jan2015) Unlicensed Medicines Policy

Statement has been included on the reverse of the request form to remind the requestor that GP's may choose not to accept the prescribing.

23/15 – Anticoagulation

Ongoing

AP

52/14 – Barrier Creams

Lothian will start the review of emollient and barrier preparations. TS to liaise with HG.

TS

29/15 RECENT LJF NEW DRUG RECOMMENDATIONS

Brimonidine – gel, 3.3% for symptomatic treatment of facial erythema of rosacea in adults. BLACK

Olodaterol – inhaler, maintenance treatment for COPD patients. BLACK

Umeclidinium/Vilanterol – inhaler, maintenance treatment for COPD patients. BLACK

30/15 SUMMARY OF LJF AMENDMENTS**LJF Amendments (March 2015)**

Hypnotics – SCP's no longer necessary for melatonin in the treatment of sleep-wake disorders in children, however the committee agreed that the SCP should continue to be used in Cumbria.

31/15 NICE TECHNOLOGY APPRAISALS

TA329 Infliximab, adalimumab and golimumab- ulcerative colitis. The guidance includes reference to Biosimilars, products with the lowest acquisition cost should be used. RED

TA330 Sofosbuvir – Hepatitis C. RED

TA331 Simprevir – Hepatitis C in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C. RED

TA332 Sipuleucel-T – prostate cancer. Not recommended.

TA333 Axitinib – renal cell carcinoma, advanced disease after failure of prior systemic treatment. RED

TA334 Regorafenib – colorectal cancer. Not recommended.

TA335 Rivoraxaban – acute coronary syndrome, recommended as an option. AMBER, no shared care

TA336 Empaglifozin – diabetes mellitus type 2. Recommended. GREEN

TA337 Rifaximin – Hepatitic encephalopathy, AMBER

TA338 Pomalidomide – multiple myeloma. NOT RECOMMENDED

32/15 NICE CLINICAL GUIDELINES**CG61 Irritable Bowel Syndrome in adults**

Reclassify Linaclotide to GREEN. LA to initiate ScriptSwitch message.

TS

LA

NG2 Bladder cancer diagnosis and management

Noted.

NG3 Diabetes in pregnancy: pre-conception to postnatal period.

Noted.

CG28 Depression in children and young people

Fluoxetine classified as AMBER after initiation by CAMMS. Treatment must include psychological therapy. All other antidepressants for children and young people – RED.

33/15 NICE CG MEDICINES OPTIMISATION

Patient safety – identifying and reporting. Consider applying principles of PINCER and use of tools like Stop / Start. Consideration to using “Fair blame culture”. Other Health Care Professionals and not just pharmacists could do the meds reconciliation. There is limited evidence of the benefits of medication review except in single disease. Offer shared decision making i.e. joint patient decision making. There should be pharmacist involvement in medicine related models. Targets for medicines reconciliation and medicines reviews.

ACTION: AL to share slides with the group. Each organization to complete a baseline assessment to reflect on process for learning from medicine related incidents.

AL
ALL

34/15 CONTRACT MONITORING

NCUHT Dermatology to implement Blueteq.

BG

35/15 MEDICINES SAFETY

Jen Whibley,(MOP) has met with Shonagh Murphy (NCUHT MSO). PB identified Carrie Eddy (UHMBT MSO) and CPFT currently recruiting, HH to confirm.

37/15 COLSEVELAM

The drug is blacklisted for licensed indication in North Lancs but not blacklisted in Cumbria. The committee approved GREEN for licensed indication and AMBER as second line option for diarrhoea.

TS

38/15 PDE-5 INHIBITORS FOR ERECTILE DYSFUNCTION

Endorsed.

ACTION: LA to amend the Supporting Section of the document.

LA

39/15 DOSULEPIN

Endorsed.

ACTION: HH to send link to CPFT Medicines site to members
LA to make suggested amendments

HH
LA

40/15 LIOTHYRONINE

Deferred to next meeting.

41/15	WARFARIN MANAGEMENT GUIDELINES Endorsed. ACTION: Suggested changes to be amended by Sue Bennett.	SB
42/15	RIVAROXABAN PATHWAY Referred back and asked to refer to Nice Guidance. Guidance not endorsed.	
43/15	BEVACIZUMAB FOR AMD DOH letter noted. NTAG decision summary not supported.	
44/15	IVABRADINE INFORMATION SHEET Information noted.	
45/15	VITAMIN D GUIDELINE, REVISED Endorsed. Incorporate list of available licensed products.	TS
46/15	NOAC PATIENT CARD Currently issued by NESCN in the North of County, LA to pass NHSE to contact to AL for distributing cards. Use of card endorsed.	LA
47/15	HEADACHE GUIDELINE TS has checked the document and it is NICE compliant. CUMBRIA APC approved to be added. Guidance approved. ACTION: LA to distribute.	TS LA
48/15	DISULFIRAM SCP Change status to Amber - Approved	TS
49/15	DRUG SAFETY UPDATE Feb - Tiotropium safety update to be added to Prescription Pad. March – Dimethyl Fumarate, HH to ensure MS service is aware, Corticosteroids e-learning module to be added to Prescription Pad.	TS HH TS
50/15	FOR INFORMATION Minutes received: NCUHT MMC Minutes Draft (9 March 2015) – No comments UHMB D&T Group (16 March 2015) – No comments	
51/15	ANY OTHER BUSINESS NTAG Treatment Appraisal document circulated by HH Lurasidone – Endorsed - BLACK	TS

Aripiprazole and Paliperidone both to be sent to CPFT MMG for approval then brought back to the APC. HH

Request by CPFT for sharp insulin needles to be prescribed by GP's when CPFT staff are administering insulin – declined. HH

Better communication requested between Consultants in Secondary Care and GP's when Enoxaparin is requested from GP's when surgery is delayed- PB

52/15 **DATE and TIME of next meeting**

Thursday, 11 June 2015, 2pm at Penrith Rugby Club
